MedTrace Logo

A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer

NCT05156424 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-12-14

No results posted yet for this study

Summary

Prostate cancer is the second most common cancer in men. Those in the intermediate/high-risk categories typically receive androgen deprivation therapy (ADT) and radiotherapy. ADT greatly reduces androgen production as prostate cancer is dependent on testosterone and dihydrotestosterone for its growth.The side effects of ADT therapy are extensive and include changes in body composition (muscle loss, bone loss and fat gain), strength, mood, physical function, sexual function and increased cardiovascular risk and fatigue. Many of these side effects can be influenced by exercise training, both resistance training and aerobic training. However, the most appropriate exercise regime for men undergoing ADT has received little research attention.

Conditions

Interventions

OTHER

Exercise

An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.

Sponsors & Collaborators

  • Irish Research Council

    collaborator OTHER

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • Waterford Instituate of Technology

    collaborator OTHER

  • Kira Murphy

    lead OTHER

Principal Investigators

  • Michael Dr Harrison, PhD · Waterford Institute of Technology

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05156424 on ClinicalTrials.gov